Tumor-associated antigens and tumor-specific antigens (HNSCC) (TAA/TSA (HNSCC))

This target refers to the broad repertoire of tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) expressed by head and neck squamous cell carcinoma (HNSCC) cells. In the context of allogeneic cell-based vaccines like HS-130, these antigens are presented by genetically modified cell lines designed to secrete chaperone proteins, such as gp96-Ig, which facilitate antigen uptake and cross-presentation by dendritic cells (Heat Biologics, 2020; ClinicalTrials.gov, NCT03808441). This approach aims to overcome the inherent heterogeneity of HNSCC by stimulating a polyvalent immune response against multiple epitopes simultaneously, rather than targeting a single protein. By utilizing allogeneic cell lines, the therapy provides a universal source of antigens that share commonalities with the patient's own tumor, potentially bypassing the need for personalized vaccine manufacturing. The primary therapeutic goal is to activate cytotoxic T lymphocytes (CTLs) to recognize and eliminate malignant cells throughout the body. This multi-antigenic targeting strategy is particularly relevant for HNSCC, which often exhibits high mutational burdens and complex immune evasion mechanisms (Strbo et al., 2013). Clinically, these antigens are targeted to enhance the efficacy of existing immunotherapies, such as checkpoint inhibitors, by increasing the breadth of the anti-tumor immune response.

Other names

HNSCC antigensTumor-associated antigensTumor-specific antigensAllogeneic tumor cell vaccine antigensHS-130 antigens

Induction of a polyvalent cytotoxic T-lymphocyte response against multiple tumor antigens via gp96-Ig mediated cross-presentation.